Lipocine (NASDAQ:LPCN) Lowered to “Hold” Rating by StockNews.com

StockNews.com lowered shares of Lipocine (NASDAQ:LPCN) from a buy rating to a hold rating in a research report released on Thursday morning.

Separately, Alliance Global Partners started coverage on Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target for the company.

Lipocine Stock Down 14.8 %

Shares of NASDAQ:LPCN opened at $4.76 on Thursday. Lipocine has a fifty-two week low of $2.35 and a fifty-two week high of $11.79. The firm’s 50 day moving average price is $4.88 and its 200 day moving average price is $5.63.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Analysts expect that Lipocine will post -0.92 EPS for the current fiscal year.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new stake in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.